ModifiedPremera BluecrossPolicy 5.01.522

Pulmonary Arterial Hypertension

Defines medical necessity, coverage, and benefit application for pharmacologic treatments of pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) for Premera Bluecross members and the providers who treat them.

Policy Summary

PayerPremera Bluecross

PolicyPulmonary Arterial Hypertension

Policy CodePolicy 5.01.522

Change TypeMaterial coverage and coding updates

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain prior authorization with documentation of diagnosis, WHO functional class, prior therapies, and hemodynamics when requesting PAH or CTEPH medications.

SourceLink

POLICY UPDATE CHANGES

Policy replaces prior policies 5.01.09 and 5.01.509 and consolidates PAH drug coverage criteria.

Adds Winrevair (sotatercept-csrk) coverage criteria including hemodynamic thresholds (PVR ≥ 5 Wood units), age and functional-class inclusion, and step therapy requirements (prior ERA and PDE5 or sGC trial).

Updated Winrevair (sotatercept-csrk) criteria to include individuals with WHO functional class IV based on ZENITH trial results.

Updated tadalafil and ambrisentan combination therapy criteria to clarify treatment is for PAH WHO Group 1 (WHO FC II–III as first-line option).

Added quantity limits to Tyvaso, Tyvaso DPI, and Yutrepia (treprostinil products).

Removed Ventavis (iloprost) from the policy as the product was discontinued by the manufacturer.

Added HCPCS/J-code mappings and additions (e.g., Revatio → J3490; Winrevair → J3590; Opsynvi → J8499) and reflected market withdrawals (Liqrev removed).

Updated criteria for Remodulin (treprostinil injection) require inadequate response or intolerance to generic treprostinil injection before Remodulin is considered.

Clarified that non-formulary exception review authorizations for listed drugs may be approved for up to 12 months and that prescribing must follow FDA product labeling.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

PVR ≥5Winrevair PVR threshold

Up to 12mApproval length

3 productsQuantity limits added

Coverage Criteria and Medical Necessity

Medical necessity criteria

Covered when ALL of the following are met

Combination therapy general criteria: Individuals have failed to demonstrate an adequate response to a single medication AND medications are from different therapeutic classes AND each medication may be considered medically necessary for the treatment of PAH

Used to determine medical necessity for combination therapy

Initial combination therapy (ambrisentan + tadalafil): Combination therapy with tadalafil and ambrisentan as first-line treatment may be considered medically necessary for treatment-naïve PAH WHO Group 1 individuals who are experiencing signs and symptoms of WHO functional class II or IIIWHO FC II or III

Based on AMBITION/related trial evidence

Opsynvi (macitentan-tadalafil) may be considered medically necessary for PAH WHO Group 1 adults experiencing signs and symptoms of WHO functional class II or IIIWHO FC II or III

Fixed-dose combination covered

Listed medication classes considered medically necessary: Phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclins (including oral, inhaled, SC/IV formulations and selexipag), and endothelin receptor antagonists are considered medically necessary for PAH WHO Group 1 when used per policy

Specific product lists and routes provided in policy

Indications for advanced pharmacologic therapy

Covered when ALL of the following are met

Diagnosis: Confirmed diagnosis of pulmonary hypertension by right heart catheterization with mean pulmonary artery pressure ≥25 mmHg (and for CTEPH, diagnostic imaging such as ventilation-perfusion scan with segmental or larger mismatched defects and pulmonary angiography to establish operability).mean PA pressure ≥25 mmHg

CTEPH operability assessment by angiography may direct surgical vs medical therapy

Baseline/conservative medical management: Documented use or consideration of conventional supportive therapies (diuretics, oxygen, heart-failure medications) and anticoagulation where indicated, and assessment for surgical options (pulmonary endarterectomy for CTEPH) prior to or in conjunction with advanced pharmacologic therapy unless contraindicated or not feasible.

Pulmonary endarterectomy is curative for eligible CTEPH patients; medical therapy indicated when surgery contraindicated or residual PH persists

Therapy selection and contraindications: Selection of advanced pharmacologic therapy should align with FDA approvals and evidence base (for example, riociguat for CTEPH); riociguat must not be combined with phosphodiesterase-5 inhibitors.

Coverage considerations for single-agent PAH therapies

Covered when evidence shows benefit in exercise capacity, functional class, or clinically meaningful endpoints and patient meets symptomatic PAH criteria.

Core eligibility: Patient has symptomatic pulmonary arterial hypertension (WHO Group 1) as studied in randomized controlled trialssymptomatic PAH

Supported by RCT populations for riociguat, selexipag, and other agents

Measured baseline and follow-up data: Documented baseline 6-minute walk distance (6MWD) and follow-up assessments including WHO functional class and hemodynamics to evaluate responsebaseline and follow-up measures

Trials consistently reported these outcomes

Agent-specific evidence of benefit: Agent has randomized trial evidence showing statistically significant improvement in primary or clinically relevant endpoints (examples include riociguat [PATENT-1], selexipag [GRIPHON], or other RCTs reporting clinically meaningful outcomes)

Coverage considerations for combination (add-on) therapy

Covered when ALL of the following are met:

Add-on therapy context: Combination therapy is used as second-line (add-on) to an existing PAH medication classadd-on to stable therapy

Meta-analyses and RCTs evaluated add-on regimens

Inadequate response or intolerance to monotherapy: Patient has inadequate clinical response or intolerance to optimized monotherapy prior to initiation of combination therapytrial of monotherapy

Trials generally enrolled individuals already on one active treatment

Expected benefit relative to MID: Anticipated improvement in 6MWD or reduction in clinical worsening consistent with trial effect sizes (typical pooled 6MWD gain ~21–25 meters) and clinical judgment regarding significance given the commonly referenced MID of ~33 meters

Not routinely covered / limited evidence — oral treprostinil as add-on

Specific restriction based on pivotal trials:

Oral treprostinil add-on coverage criteria: Coverage for add-on oral treprostinil may be restricted because the FREEDOM-C and FREEDOM-C2 trials did not meet their primary efficacy endpoints; documentation should include clinical rationale and prior alternatives tried before add-on oral treprostinil is authorizedfailed to meet primary endpoint

Neither FREEDOM-C nor FREEDOM-C2 met the primary efficacy endpoint at 16 weeks

Monotherapy (FDA‑approved classes)

Covered when ALL of the following are met

Monotherapy medical necessity: Patient has WHO Group 1 PAH and is being considered for an FDA‑approved medication in prostanoids, endothelin‑receptor antagonists, phosphodiesterase‑5 inhibitors, or riociguat; evidence supports improvements in clinically relevant outcomes.

Evidence from multiple RCTs and meta‑analyses supports monotherapy; riociguat contraindicated with PDE5 inhibitors.

Combination therapy (second‑line)

Covered when ALL of the following are met

Combination therapy indication: Patient remains symptomatic or has inadequate response on monotherapy and combination therapy uses medications from different mechanistic classes as second-line add-on therapy; choice guided by clinician judgment and existing trial evidence.

Combination therapy improves exercise capacity; impact on mortality and clinical worsening inconclusive; few RCTs define optimal combinations.

Sotatercept (Winrevair) coverage

Covered when ALL of the following are met

Sotatercept (Winrevair) coverage: Patient is aged ≥18 years with a confirmed diagnosis of PAH (WHO Group 1) and has WHO functional class consistent with pivotal trials (eg, FC II–III as in STELLAR, or higher‑risk FC III/IV as in ZENITH) AND has been receiving background standard‑of‑care PAH therapies AND prescriber documents rationale for sotatercept add‑on; sotatercept is prescribed by or in consultation with a cardiologist or pulmonologist.Age ≥18; WHO FC as specified

STELLAR and ZENITH trial results support efficacy; safety monitoring and labeled exclusions apply.

Investigational / Not Medically Necessary

Investigational agents: Use of simvastatin, atorvastatin, and imatinib for PAH is considered investigational and not medically necessary due to insufficient evidence or unfavorable risk–benefit (including serious adverse events noted with imatinib).

Imatinib trials showed limited efficacy and serious adverse events (subdural hematoma) particularly when combined with anticoagulation.

Riociguat (CTEPH)

Covered when ALL of the following are met

Riociguat for CTEPH: Patient has inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy, is not receiving a PDE5 inhibitor (riociguat is contraindicated with PDE5 inhibitors), and riociguat dosing is titrated per labeling; riociguat is considered medically necessary for these indications.

CHEST‑1 demonstrated improvement in 6MWD and hemodynamics; no evidence supports riociguat for preoperative PVR reduction in surgical candidates.

CTEPH perioperative therapy

Conditional guidance (evidence limited)

Preoperative pulmonary vascular reduction: For CTEPH patients being evaluated for pulmonary endarterectomy with markedly elevated PVR, selective use of PAH‑specific therapies has been studied (small RCTs, retrospective series) but evidence is heterogeneous and limited; coverage decisions should consider surgical candidacy, extreme PVR thresholds, multidisciplinary input, and that riociguat has no trials in the preoperative setting.PVR >1100 Wood units associated with increased operative mortality

Studies report mixed perioperative effects; PAH drugs should not replace or delay evaluation for pulmonary endarterectomy.

Medical necessity — riociguat and PAH-specific medications

Covered when ALL of the following are met (per evidence and guideline-concordant indications):

Indication concordance

WHO group and surgical candidacy: WHO Group 1 PAH OR WHO Group 4 CTEPH in individuals who are inoperable or have persistent PH after pulmonary endarterectomy
References: RCT evidence and guideline guidance

Contraindications and co-therapy: No contraindicated concurrent therapies are present (for example, riociguat must not be used with PDE5 inhibitors)

Contraindication explicitly stated in policy

Guideline-concordant functional status: Use and choice of initial or combination therapy should consider WHO functional class and guideline recommendations (eg, initial ambrisentan + tadalafil for FC II–III where guideline-supported)

See ACCP and ESC/ERS guideline summaries

Guideline- and FDA-aligned coverage considerations

Coverage should align with guideline recommendations and FDA-approved indications as summarized:

FDA or guideline alignment: Agent is FDA-approved for the patient’s WHO Group and indication OR there is guideline support for use in the specific clinical scenario (eg, riociguat for inoperable/persistent CTEPH)

Refer to regulatory status and guideline sections in policy

CTEPH-specific conditions: Use of PAH-specific medications is appropriate when the patient is inoperable for pulmonary endarterectomy, has persistent PH after endarterectomy, or is a high-risk surgical candidate who may benefit from presurgical IV epoprostenol; PAH drugs should not replace or delay evaluation for endarterectomy.

Guideline and consensus recommendations referenced

Combination therapy guidance: For selected high-risk patients, initial combination therapy (ERA + PDE5i, or triple therapy including prostacyclin analogues) is supported by ESC/ERS guidelines; macitentan/tadalafil fixed-dose is FDA-approved for PAH FC II–III and informs coverage decisions.

Some combinations (eg, macitentan+tadalafil+selexipag) are not routinely recommended

Product-specific coverage criteria (recent updates)

Covered with criteria when product-specific requirements in policy are met

Winrevair (sotatercept-csrk): Coverage criteria updated to include individuals with WHO functional class III or IV based on ZENITH trial results demonstrating reduced risk of first event (all-cause death, lung transplant, or PAH‑worsening hospitalization).

Refer to product-specific criteria for hemodynamic thresholds, prior ERA and PDE5/sGC trial requirements

Tadalafil + Ambrisentan combination therapy: Initial combination therapy with tadalafil and ambrisentan is covered as first-line for individuals with PAH WHO Group 1 who are WHO FC II or III; evidence showed lower risk of clinical-failure events versus monotherapy.WHO FC II–III

Policy clarified to specify PAH WHO Group 1

Treprostinil products and quantity limits: Tyvaso, Tyvaso DPI, and Yutrepia have added quantity limits; Tyvaso DPI is included as an inhalation powder formulation with similar administration frequency to Tyvaso solution.

Notable Coverage Criteria Revisions

Coverage updates and criteria revisions noted in policy history (selected items):

Winrevair inclusion: Winrevair (sotatercept-csrk) criteria updated to include individuals with WHO functional class IV following review of ZENITH trial data.

Applies to WHO Group 1 PAH

Tadalafil + Ambrisentan combination: Combination therapy with tadalafil and ambrisentan added as first-line treatment for individuals with PAH WHO Group 1 and WHO functional class II or III (clarified in updates).

Effective per policy history

Remodulin step: Remodulin (treprostinil injection) criteria updated to require inadequate response or intolerance to generic treprostinil injection first (effective Jan 3, 2025).

Provider notification window noted in history

Product discontinuation:

Use of PAH‑approved medications outside of WHO Group 1 pulmonary arterial hypertension is considered investigational. Specifically, pharmacologic therapies listed in this policy (including but not limited to prostanoids, endothelin receptor antagonists, PDE5 inhibitors, riociguat, selexipag, and sotatercept) are investigational for non‑PAH pulmonary hypertension (WHO Groups 2–5) and for other unspecified conditions (examples: PH due to left heart disease; PH associated with lung disease/hypoxemia; chronic thrombotic/embolic disease when not classified as Group 4).

Combination use of riociguat with a phosphodiesterase‑5 (PDE5) inhibitor is explicitly contraindicated. Requests for concurrent riociguat plus PDE5 inhibitor therapy should be avoided and will be reviewed for contraindication per policy (riociguat must not be combined with sildenafil, tadalafil, or other PDE5 inhibitors).

One randomized trial of intravenous treprostinil was terminated early for safety after a death occurred during catheter placement; this safety event influenced interpretation of IV treprostinil trial results and may limit applicability of that trial's findings.

Randomized controlled trial evidence does not support routine use of statins as PAH‑specific therapy. Trials of simvastatin and atorvastatin failed to demonstrate clinically meaningful benefit for PAH, and therefore statins are not supported as PAH‑specific treatment based on available RCT data.

Specific agents — simvastatin, atorvastatin, and imatinib — are explicitly listed as investigational for the treatment of PAH and are considered not medically necessary due to insufficient evidence or unfavorable risk–benefit profiles.

There is insufficient evidence to support use of riociguat or other PAH‑specific medications to reduce elevated preoperative pulmonary vascular resistance in patients who are candidates for pulmonary endarterectomy. Use of these agents for preoperative PVR lowering in operable CTEPH is considered investigational.

PAH‑specific medical therapy should not be used in lieu of pulmonary endarterectomy or to delay evaluation for pulmonary endarterectomy in patients who are surgical candidates. Evaluation for and consideration of pulmonary endarterectomy remain primary for operable CTEPH, and medical therapy is reserved for inoperable cases, residual PH after surgery, or select high‑risk situations.

Ventavis (iloprost) has been removed from the policy's coverage statements because the product was discontinued by the manufacturer; related HCPCS reporting guidance was updated accordingly.

This medical policy and its coverage criteria do not apply to Medicare Advantage plans. Coverage determinations remain subject to the member's benefit plan terms and exclusions.

Other advanced or alternative therapies (for example, imatinib and statins such as simvastatin or atorvastatin) are considered investigational for PAH. Imatinib in particular is discouraged for off‑label use because trials demonstrated limited efficacy and significant safety concerns (including serious adverse events and subdural hematomas when combined with anticoagulation).

Short‑term surrogate endpoints commonly used in PAH trials — such as change in the 6‑minute walk distance (6MWD) alone — have uncertain value for predicting long‑term, clinically meaningful outcomes like survival, transplantation, or hospitalization. Reliance solely on small, short‑duration 6MWD changes without corroborating clinical outcomes may be insufficient to justify therapy.

Randomized trial data do not support the use of statins (simvastatin, atorvastatin) to treat PAH. Clinical trials terminated early for futility or showing no benefit indicate statins are not supported as PAH‑directed therapy.

Imatinib is discouraged for PAH due to an unfavorable risk–benefit profile observed in trials: efficacy was limited and serious adverse events (including subdural hematoma in patients on concomitant anticoagulation) were reported, leading reviewers to strongly discourage off‑label use.

Use of simvastatin, atorvastatin, or imatinib for treating PAH is considered investigational and therefore not medically necessary because of insufficient evidence of benefit or significant safety concerns.

There is no evidence to support routine use of riociguat or other PAH‑specific medications to lower pulmonary vascular resistance preoperatively in operable CTEPH patients. Such preoperative use is investigational and should not replace surgical evaluation or be used as a bridge to delay pulmonary endarterectomy when the patient is a surgical candidate.

Historical investigational therapies and prior policy listings (for example, earlier assessment of imatinib and statins) are documented in the policy history. Over time the policy has been updated to reflect trial results, safety signals, and product availability changes.

Billing Codes and Key Clinical Thresholds

HCPCS and related codesHCPCS

J1325	Injection, epoprostenol (use to report: Flolan and Veletri), 0.5 mg
J3285	Injection, treprostinil (use to report: Remodulin), 1 mg
J3490	Unclassified Drugs (Use to report: Uptravi and Yutrepia)
J3590	Unclassified biologics (use to report: Winrevair)
J7686	Treprostinil (Tyvaso), inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, 1.74 mg
K0455	Infusion pump used for uninterrupted parenteral administration of medication (e.g. epoprostenol or treprostinil)
Q4074	Iloprost, inhalation solution, FDA-approved final product, noncompounded, administered through DME, up to 20 mcg

Specialty drug codes (grouped)NDC

NDC	Specialty drug billing (prostanoids, treprostinil, epoprostenol, riociguat, endothelin-receptor antagonists, PDE5 inhibitors) as applicable

Additional specialty drug referencesmixed

epoprostenol (FLOLAN/Veletri)	continuous IV infusion for PAH
treprostinil (REMODULIN/TYVASO/ORENITRAM/YUTREPIA)	SC/IV/inhalation/oral formulations for PAH or PH-ILD per specific product

HCPCS mappings and additionsHCPCS

J3490

Revatio (mapped to J3490 per policy)

HCPCS additionsHCPCS

J3590	Winrevair (sotatercept-csrk)
J8499	Opsynvi (macitentan-tadalafil) and Liqrev (when previously listed)

HCPCS code updates and mappingsHCPCS

J3285	listed previously for specific drug indication updates (e.g., Veletri reference)
J3490	used for various PAH drug dosage forms; parenthetical updated to include Yutrepia
J3590	Winrevair (sotatercept-csrk)
J8499	historical use for Opsynvi and Liqrev (removed)
Q4704	used to report Ventavis (iloprost) — removed

Pulmonary Vascular Resistance (PVR) — Policy threshold

PVR threshold>= 5 Wood units (measured by right heart catheterization)

Associated PCWP requirementPCWP <= 15 mmHg (policy lists as additional hemodynamic requirement)

Use contextRequired for Winrevair (sotatercept-csrk) eligibility per policy

Hemodynamic thresholds for diagnosis and CTEPH criteria

Mean pulmonary artery pressure (mPAP)> 25 mmHg confirms pulmonary hypertension diagnosis (RHC)

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization required for advanced PAH therapies and add-on prostacyclin therapy; approvals and non-formulary exception reviews may be authorized for up to 12 months when drug-specific coverage criteria are met and chart notes show continued clinical benefit.

Prior authorization is expected for FDA‑approved PAH medications and recently added agents (e.g., riociguat, sotatercept/Winrevair, Opsynvi) when used for FDA‑approved indications (WHO Group 1).
Add‑on prostacyclin therapy (including oral treprostinil) may require prior authorization and clinical justification given mixed evidence for benefit as add‑on therapy.
Authorizations (including non‑formulary exception reviews) may be approved up to 12 months; reauthorization may be granted for up to 12 months if continued clinical response is documented.

Note

No Explicit PA or Step‑Therapy Rules in Some Content

Some source content describes clinical trial results and background evidence without prescribing operational prior authorization or step‑therapy sequencing rules. Where no explicit PA/step requirements are specified in the policy text, reviewer should default to contacting the payer for direction or follow usual medical/pharmacy benefit processes.

Clinical Background and Evidence Summary

Pulmonary arterial hypertension (PAH, WHO Group 1) is characterized by progressive narrowing and remodeling of small pulmonary arteries, leading to elevated pulmonary arterial pressure, right ventricular overload, and eventual right heart failure. Treatment goals for PAH include improving exercise capacity and functional class, reducing clinical worsening, and optimizing hemodynamics. Advanced therapies (prostanoids, endothelin receptor antagonists, PDE5 inhibitors, soluble guanylate cyclase stimulators, and newer agents such as sotatercept) are used to achieve these goals when medically necessary and guideline‑concordant.

Key Definitions and Clinical Terms

WHO functional class — II–IV

Applicable WHO functional classesWHO Functional Class II–IV (policy references FC II, III, and IV in therapy indications)

Class II descriptionSymptoms with ordinary activity; comfortable at rest

Class IV descriptionSymptoms at rest; inability to perform any physical activity without symptoms

PVR threshold for Winrevair eligibility

PVR requirement for Winrevair>= 5 Wood units required for sotatercept (Winrevair) eligibility per policy

Measurement methodPVR measured by right heart catheterization

Age requirement context

Policy Updates and Revision History

2026-04-01Criteria revisionLatest

Updated Winrevair (sotatercept-csrk) criteria to include individuals with WHO functional class IV and clarified tadalafil + ambrisentan combination therapy is for PAH WHO Group 1; added quantity limits to Tyvaso, Tyvaso DPI, and Yutrepia; removed Ventavis (iloprost) due to manufacturer discontinuation.

2025-11-01Code and product addition

Added Yutrepia (treprostinil) to prostacyclins for PAH WHO Group 1 and added Yutrepia to HCPCS J3490 parenthetical.

2025-07-01

Policy Summary

PayerPremera Bluecross

PolicyPulmonary Arterial Hypertension

Policy CodePolicy 5.01.522

Change TypeMaterial coverage and coding updates

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain prior authorization with documentation of diagnosis, WHO functional class, prior therapies, and hemodynamics when requesting PAH or CTEPH medications.

SourceLink

On This Page

Combination contraindication explicitly stated

significant trial outcome

See trial summaries in policy

expected 6MWD change

Meta-analyses report pooled WMD 21–25 m; clinical significance may be uncertain

administration frequency: four times daily (as applicable)

Quantity limits require adherence or prior authorization justification

Remodulin (treprostinil injection) step requirement: Remodulin criteria require inadequate response or intolerance to generic treprostinil injection before Remodulin is considered (effective Jan 3, 2025).trial of generic treprostinil injection

Operational step-therapy requirement

Ventavis (iloprost) removed from the policy due to manufacturer discontinuation (HCPCS Q4704 removed).

Operational change reflected in history

European CTEPH criteria

PCWP <= 15 mmHg and PVR > 2 Wood units (European guideline criteria referenced)

Policy hemodynamic examplePolicy requires PCWP <=15 mmHg alongside elevated PVR for Winrevair; mPAP >25 mmHg used to confirm PH diagnosis

Minimum follow-up duration in included combination therapy trials

Typical trial follow-up>= 8-12 weeks minimum follow-up required in many combination therapy RCTs and meta-analyses

AHRQ review inclusionMeta-analyses and RCTs included trials with at least 12 weeks of follow-up (AHRQ review referenced)

Fox et al. meta-analysisIncluded trials with at least 12 weeks of follow-up; pooled analyses reflect short trial durations

Minimal clinically important difference (MID) for 6MWD

Minimal clinically important difference (6MWD MID)33 meters cited as the commonly accepted MID benchmark

Combination therapy effects vs MIDPooled combination therapy 6MWD gains (~21–25 m) are often below the 33 m MID

Clinical significance notePolicy notes uncertainty of clinical significance when improvements are less than MID

Minimum baseline 6MWD for FREEDOM trials

Minimum baseline 6MWD requirement>= 100 meters (minimum baseline 6MWD eligibility in FREEDOM trials)

FREEDOM trial contextFREEDOM-C and FREEDOM-C2 enrolled participants with baseline 6MWD >=100 m when assessing add-on oral treprostinil

Use for authorizationDocumentation of baseline 6MWD may be requested when considering add-on oral treprostinil

Preoperative PVR and operative mortality

Preoperative PVR associated risk>1100 Wood units associated with increased operative mortality (operative mortality 6%–10% reported)

Perioperative contextMarkedly elevated preoperative PVR may prompt consideration of PAH-specific preoperative management in selected high-risk patients, but evidence is limited

Policy implicationPolicy notes lack of high-quality evidence to support routine preoperative pharmacologic lowering of PVR for operable CTEPH

Selexipag / Sotatercept dosing summary

Starting doseSotatercept (Winrevair) starting dose: 0.3 mg/kg subcutaneously

Target/maintenance doseTarget dose: 0.7 mg/kg subcutaneously every 3 weeks

Administration routeSubcutaneous injection every 3 weeks per prescribing information

Riociguat dosing summary

Riociguat dose rangeRiociguat titrated to 0.5–2.5 mg three times daily (dose optimization over first 8 weeks)

Dose optimization periodDose titration/optimization conducted during initial 8 weeks in CHEST-1, then maintained for additional 8 weeks

Contraindication noteRiociguat must not be combined with PDE5 inhibitors (contraindicated)

Sotatercept (Winrevair) dosing summary

Sotatercept starting doseStarting dose: 0.3 mg/kg subcutaneously

Sotatercept target dose and intervalTarget dose: 0.7 mg/kg every 3 weeks (subcutaneous)

Indication summaryApproved for adults with PAH to improve exercise capacity and WHO functional class and reduce risk of clinical worsening events

Quantity limits — treprostinil products

Products with quantity limitsQuantity limits applied to Tyvaso (treprostinil inhalation), Tyvaso DPI (treprostinil inhalation powder), and Yutrepia (treprostinil)

Administration frequencyPolicy notes Tyvaso and Tyvaso DPI are administered four times daily

Authorization implicationRequests exceeding quantity limits may be denied or require justification per policy history

Non-formulary exception authorization duration

Authorization durationNon-formulary exception review authorizations may be approved for up to 12 months

Documentation requirementProviders should document non-formulary rationale when requesting exception reviews

Operational notePolicy history clarifies 12-month maximum for non-formulary exception approvals

Clinical trial summaries (e.g., FREEDOM, SERAPHIN, PATENT, STELLAR, ZENITH) are included for context but do not, by themselves, define PA steps unless the policy explicitly states them.
No step therapy sequencing requirements are specified in certain sections; absence of a stated rule does not imply coverage—obtain PA when in doubt.

Documentation Required

Documentation Requirements for Medical Necessity

Providers must submit detailed documentation to support medical necessity requests for PAH therapies; insufficient documentation may delay or deny authorization.

Required records: office visit notes with diagnosis, relevant history, physical exam, and medication history; prescriber specialty (cardiologist or pulmonologist) when required (e.g., Winrevair).
Diagnostic documentation: hemodynamic confirmation from right heart catheterization (e.g., mean PAP >25 mmHg, PVR threshold per drug criteria such as ≥5 Wood units for sotatercept; PCWP ≤15 mmHg for WHO Group 1).
Clinical trial evidence summaries and rationale should be provided when requesting coverage based on trial‑like indications or add‑on use.
Required clinical measures for review: baseline and follow‑up 6‑minute walk distance (6MWD), WHO/NYHA functional class, hemodynamics (RHC values), and documentation of adverse events or intolerance.
CTEPH requests for riociguat must document ineligibility for pulmonary endarterectomy or persistent PH after endarterectomy; riociguat is contraindicated with PDE5 inhibitors (do not co‑prescribe).
Documentation must demonstrate prior therapies tried and response (e.g., inadequate response or intolerance to an ERA and a PDE5 inhibitor or riociguat trial where specified for Winrevair).

Step Therapy

Combination and Step Therapy Considerations

Combination therapy and sequencing: guidelines and policy permit both first‑line and step‑up strategies in specific circumstances; documentation of prior inadequate response or use of agents from different classes is required for many add‑on approvals.

Combination therapy as second‑line (add‑on) is supported by RCTs and meta‑analyses and may be considered medically necessary when individuals have failed to demonstrate adequate response to monotherapy and drugs are from different therapeutic classes.
Guideline‑informed sequencing: ACCP and ESC/ERS guidelines support initial combination therapy with ambrisentan + tadalafil for select treatment‑naive WHO FC II–III patients; the policy allows tadalafil + ambrisentan as first‑line for select WHO FC II and some FC III patients.
Providers must document prior inadequate response/intolerance to prior agents when the policy criteria specify a step (e.g., Remodulin requires prior inadequate response or intolerance to generic treprostinil injection).
No universal step sequencing is mandated across the policy; where the policy lacks explicit sequencing rules, follow the drug‑specific criteria in the policy or obtain PA guidance.

Denial Risk

Investigational Agents and Exclusions

Investigational or off‑label agents without FDA‑approved PAH indications (e.g., imatinib, simvastatin, atorvastatin) are considered investigational and are generally denied; withdrawn products are not covered.

Imatinib is discouraged for PAH due to safety concerns and may be denied.
Statins (simvastatin, atorvastatin) lack efficacy evidence for PAH and are considered investigational.
Withdrawn products (e.g., Liqrev) are removed from the policy and are not covered.

Billing Rule

HCPCS / J‑Code Mapping and Billing Notes

Billing and HCPCS/J‑code considerations: updated code mappings exist for newly added products and providers should use current codes when requesting prior authorization or submitting claims.

Recent HCPCS/J‑code updates include mappings for sotatercept (J3590 noted previously), Opsynvi, and Yutrepia additions to the J3490 parenthetical — verify current payer coding guidance before submission.
Providers should obtain prior authorization using the updated HCPCS mappings where applicable; some codes (e.g., Q4704 for Ventavis) have been removed.
Infusion pumps and home infusion charges: back‑up pump costs may be included in home infusion therapy charges or captured in applicable HCPCS codes.

Note

Quantity Limits, Benefit Application, and Limitations

Quantity limits, benefit applicability, and plan limitations: the policy imposes quantity limits on certain inhaled treprostinil products and coverage is subject to member benefit plan terms.

Quantity limits were added for Tyvaso (treprostinil), Tyvaso DPI (treprostinil), and Yutrepia (treprostinil). Requests exceeding quantity limits may be denied or require additional justification.
Benefit application: specify whether the drug is managed under the medical or pharmacy benefit (policy lists several agents under each benefit).
Coverage is subject to the member's benefit plan — consult the member benefit booklet or customer service; this policy does not apply to Medicare Advantage.

Policy pairs PVR threshold with other Winrevair criteria (eg age >=18, PCWP <=15 mmHg)

Pulmonary hypertension (PH) — diagnostic hemodynamic criteria

PH diagnostic mPAP>= 25 mmHg (mean pulmonary arterial pressure) on right heart catheterization confirms pulmonary hypertension

Additional CTEPH hemodynamicsEuropean criteria: PCWP <=15 mmHg and PVR >2 Wood units for CTEPH characterization

Policy diagnostic documentationPolicy requires RHC hemodynamics (mPAP, PCWP, PVR) to confirm diagnosis and support coverage decisions

CTEPH — description and cause

CTEPH descriptionChronic thromboembolic pulmonary hypertension caused by organized thrombi and vascular remodeling after acute or chronic pulmonary embolism

DiagnosisDiagnosed by ventilation-perfusion scan with segmental or larger mismatched defects and confirmed by pulmonary angiography

Treatment rolePulmonary endarterectomy is recommended for eligible patients; riociguat is FDA-approved for inoperable or persistent CTEPH

6MWD — primary outcome definition

6MWD definitionSix-minute walk distance (6MWD) — primary efficacy outcome in many PAH trials, reported as change from baseline to trial endpoint

Use in trialsUsed across pivotal RCTs (e.g., FREEDOM, STELLAR, CHEST-1) to assess exercise capacity

DocumentationPolicy expects baseline and follow-up 6MWD assessments to evaluate response in authorization reviews

Primary composite endpoint (SERAPHIN)

SERAPHIN primary composite endpointComposite of morbidity (atrial septostomy, lung transplantation, or worsening of PAH) and all-cause mortality

Trial populationSERAPHIN randomized 742 individuals; primary endpoint and secondary outcomes included 6MWD and WHO functional class

Clinical relevanceComposite used to capture clinically meaningful events beyond exercise capacity

6MWD — exercise capacity metric

6MWD as exercise metric6MWD is an exercise capacity metric used in PAH trials to measure change from baseline to endpoint

Trial examplesUsed in trials such as FREEDOM-M, STELLAR (sotatercept), CHEST-1 (riociguat), and GRIPHON (selexipag)

Interpretation caveatShort-term 6MWD improvements may not reliably predict long-term clinical outcomes

Primary composite endpoint (GRIPHON)

GRIPHON primary composite endpointComposite of death from any cause or a complication related to pulmonary arterial hypertension up to end of treatment period

Trial size/outcomeGRIPHON enrolled 1156 individuals and showed selexipag reduced risk of the composite endpoint

Endpoint componentsIncludes death and PAH-related complications (disease progression, hospitalization, etc.)

CTEPH subgroup and CHEST-1 trial

CTEPH subgroup and trialCTEPH is evaluated separately; riociguat was studied in CHEST-1 in inoperable or persistent CTEPH

Trial outcomesCHEST-1 showed significant 6MWD improvement and hemodynamic benefits with riociguat

Surgical assessmentPulmonary angiography used to determine operability and guide therapy decisions

Sotatercept (Winrevair) — description and trial outcomes

MechanismSotatercept (Winrevair) is an activin signaling inhibitor targeting vascular proliferation

Key STELLAR outcomesSTELLAR showed median +41 m 6MWD at 24 weeks and large reductions in clinical worsening events

Safety signalsPrescribing information includes warnings for increased hemoglobin, thrombocytopenia, severe bleeding, embryo-fetal toxicity, and impaired fertility

Riociguat — sGC stimulator and contraindication

Mechanism and indicationRiociguat is a soluble guanylate cyclase (sGC) stimulator with RCT evidence for PAH and inoperable/persistent CTEPH

Dosing summaryTitrated to 0.5–2.5 mg three times daily per labeling (dose optimization over first 8 weeks)

ContraindicationRiociguat is contraindicated in combination with phosphodiesterase type 5 inhibitors (PDE5i)

CTEPH — PEA recommended therapy and role of pharmacotherapy

CTEPH managementPulmonary endarterectomy is the recommended therapy for eligible CTEPH patients; pharmacotherapy (e.g., riociguat) used for inoperable or residual disease

Surgical candidacyOperability assessment via pulmonary angiography guides decision for endarterectomy versus medical therapy

AnticoagulationIndefinite therapeutic anticoagulation is recommended for CTEPH unless contraindicated

PAH (WHO Group 1) — treatment goals and therapy types

PAH treatment goalsImprove exercise capacity, WHO functional class, and reduce clinical worsening/hospitalizations

Therapy classesProstacyclin analogs, endothelin receptor antagonists, PDE5 inhibitors, sGC stimulators, prostacyclin receptor agonists, and activin signaling inhibitors

Evidence basisMultiple RCTs and meta-analyses support use of FDA-approved agents for WHO Group 1 PAH

CTEPH (WHO Group 4) — role of endarterectomy and pharmacotherapy

CTEPH role of endarterectomyPulmonary endarterectomy is primary treatment for operable CTEPH; medical therapy reserved for inoperable or residual disease

Pharmacotherapy roleRiociguat is FDA-approved for inoperable or persistent CTEPH; other PAH drugs may be used selectively per guidelines

Perioperative cautionPAH-specific medications should not be used in lieu of surgery or to delay evaluation for endarterectomy

WHO functional class (FC) — severity classification and therapy indications

WHO FC linkage to therapyWHO Functional Class guides therapy selection; policy references FC II–IV for various indications

ExamplesInitial combination ambrisentan + tadalafil suggested for FC II–III; parenteral prostanoid for rapidly progressing FC III or FC IV

DocumentationPolicy requires documentation of WHO functional class when requesting PAH-specific therapies

WHO Functional Class — guidance for therapy selection

Use in authorization decisionsWHO Functional Class is referenced to guide selection of therapies and eligibility (e.g., Winrevair, Opsynvi, initial combination therapy)

Policy updatesWinrevair criteria expanded to include WHO FC IV based on ZENITH; initial combination therapy clarified for FC II–III

Clinical implicationPrescribers should document WHO FC when requesting coverage for specific PAH agents

Administrative update

Removed Liqrev (sildenafil) from the policy after market withdrawal and clarified non-formulary exception review authorizations may be approved up to 12 months; updated HCPCS code name mappings.

2024-08-01Coverage additions and coding

Added coverage criteria for Winrevair (sotatercept-csrk) and Opsynvi (macitentan-tadalafil); added HCPCS codes J3590 (Winrevair) and J8499 (Opsynvi and Liqrev); added sildenafil 10 mg/mL oral suspension to PDE-5 inhibitors earlier in the year.

2024-02-01Coding addition

Added sildenafil 10 mg/mL oral suspension (generic of Revatio) to PDE-5 inhibitors and mapped Revatio to HCPCS J3490.

2023-06-01Interim review

No new evidence identified requiring changes to coverage criteria during the June 1, 2023 annual review.

2023-02-01Product addition

Added Tadliq (tadalafil) 20 mg/5 mL oral suspension to the list of PDE5 inhibitors.

2022-10-01Coverage update

Added coverage for first-line combination therapy with tadalafil and ambrisentan for WHO FC II–III and added Tyvaso DPI formulation to the policy.